Reducing toxicity in future ADC design and combination therapy strategies

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinomaПодробнее

Antibody drug conjugatesADCs current progress and selection of preclinical animal modelsПодробнее

Protecting Delta-Sigma ADC: RTD OverviewПодробнее

Challenges and Advances in Antibody-Drug Conjugates.Подробнее

The basic knowledge of ADC - Creative BiolabsПодробнее

Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical ModelПодробнее

Advances in ADC Development and Preclinical ModelsПодробнее

Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational CombinationsПодробнее

Integrated Strategies to Accelerate Preclinical Development of Antibody-Drug ConjugatesПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

Antibody Therapy in Acute Leukemia: Clinical Considerations in Conjunction With HSCTПодробнее

Education Session HER2+ Breast Cancer Updates from the Clinic and the LabПодробнее

Antibody-Drug Conjugates (ADCs): Current Research and Overcoming Challenges - Webinar PlaybackПодробнее

Antibody Drug Conjugates for CancerПодробнее

JNM Podcast Episode 1: The Future of FAPI TherapyПодробнее

What is ADC? - Creative BiolabsПодробнее

How to mitigate risk during ADC development with multi-parameter stability characterizationПодробнее